CRO 行业分析报告09年

maxsese

好东西 大家一起分享

报告目录
2009 年度中国医药研发外包（CRO）市场深度研究及2010 年投资分析报告
·······················································································································10
第一章 医药研发外包（CRO）概述······························································10
第一节 CRO 研究基础···························································································································10
一 CRO 产业定义························································································································· 10
二 CRO 产生背景························································································································· 10
三 CRO 服务范围························································································································· 11
第二节 国内外CRO 市场······················································································································12
一 国际CRO 行业发展················································································································· 12
二 国内CRO 总体发展················································································································· 14
第二章 2008-2009 年全球医药市场背景························································15
第一节 2008 年全球医药市场················································································································15
一 2008 年全球医药并购分析······································································································ 16
二 产业多元化布局······················································································································· 16
三 奥巴马新政立法考验··············································································································· 16
四 医药研发外包权重加大··········································································································· 17
五 2008 年新药审批谨慎·············································································································· 17
六 2008 年仿制药竞争加剧·········································································································· 18
第二节 2008 年全球制药企业················································································································19
一 2008 年全球药品销售规模······································································································ 19
二 2008 年医药巨头经营分析······································································································ 20
三 2008 年医药企业排名·············································································································· 22
四 2008 年医药企业研发投入······································································································ 23
第3 页 共141 页
第三节 全球医药企业研发现状·············································································································28
一 研发投入热潮涌动··················································································································· 29
二 利益决定研发取舍··················································································································· 30
三 拯救研发产品线······················································································································· 31
第四节 世界新药研发趋势·····················································································································31
一 研发投入不断增长··················································································································· 33
二 研发风险不断增加··················································································································· 34
三 新药上市数量持续减少··········································································································· 34
四 新药研发的技术动向··············································································································· 35
五 热点开发药物·························································································································· 36
六 我国新药研发现状··················································································································· 37
第五节 2009 年全球医药并购················································································································38
一 2008 年全球医药并购·············································································································· 38
二 2009 年医药并购分析·············································································································· 41
第三章 2008-2010 年全球CRO 产业分析·····················································42
第一节 CRO 产业发展背景分析···········································································································42
一 跨国公司研发方式演变··········································································································· 42
二 跨国公司研发外包动因··········································································································· 43
第二节 全球CRO 市场规模分析··········································································································44
一 2008-2010 年全球新药研发费用分析····················································································· 44
二 2008-2010 年全球CRO 市场规模··························································································· 45
三 2007 年全球CRO 企业格局···································································································· 45
四 全球新药研发外包发展前景分析··························································································· 47
第三节 全球CRO 业务市场结构··········································································································48
一 新药研发外包业务分析··········································································································· 48
二 2007 年新药研发外包业务结构······························································································ 49
第4 页 共141 页
三 研发外包服务业务结构发展特点··························································································· 50
第四节 全球CRO 区域市场分析··········································································································52
一 全球CRO 市场区域格局········································································································· 52
二 美国CRO 产业分析················································································································· 52
三 印度CRO 市场分析················································································································· 56
四 台湾地区CRO 市场分析········································································································· 57
第五节 全球顶级CRO 企业扫描··········································································································58
一 Quintiles Transnational ············································································································· 58
二 Covance ···································································································································· 58
三 PAREXEL International············································································································ 59
第六节 全球医药外包市场预测·············································································································60
一 亚洲低成本优势正在淡化······································································································· 60
二 宏观经济对医药外包影响······································································································· 62
三 医药外包前景预测··················································································································· 64
第四章 2008-2009 年中国CRO 医药产业背景··············································65
第一节 2009 年1-9 月行业运行·············································································································65
一 2009 年医药行业增长情况······································································································ 66
二 2009 年医药行业投资情况······································································································ 66
三 2009 年医药行业创新情况······································································································ 68
四 2009 年医药行业生产情况······································································································ 69
五 2009 年医药行业销售情况······································································································ 72
六 2009 年医药行业进出口情况·································································································· 74
七 2009 年医药行业价格情况······································································································ 76
第二节 2008-2009 年生物制药运行······································································································78
一 2003－2009 年行业资产规模·································································································· 78
二 2003－2009 年行业企业数量·································································································· 79
2009 年度中国医药研发外包（CRO）市场深度研究及2010 年投资分析报告 报告编号：CRO-F-100607
第5 页 共141 页
三 2003－2009 年行业销售收入·································································································· 80
四 2003－2009 年行业利润总额·································································································· 81
五 2003－2009 年行业毛利率······································································································ 82
六 2003－2009 年行业利润率······································································································ 83
第三节 中国医药产业R&D 分析··········································································································84
一 医药行业R&D 现状················································································································ 84
二 生物制药R&D 现状················································································································ 84
第四节 中国居民医疗保健支出·············································································································84
一 1995-2008 年居民医疗支出规模···························································································· 84
二 2008 年医疗保健支出同GDP 关系··························································································· 85
三 2008 年人均收入同医疗支出关系··························································································· 87
四 2008 年人口城镇化和老龄化分析··························································································· 88
五 中药行业 “十一五”两大任务····························································································· 91
第五章 2008-2009 年中国CRO 市场研究·····················································91
第一节 中国CRO 发展分析··················································································································92
一 CRO 在国内的发展状况·········································································································· 92
二 CRO 在我国的发展前景·········································································································· 93
第二节 国内CRO 市场规模分析··········································································································94
一 2004-2008 年中国CRO 市场规模··························································································· 94
二 国内企业业务结构分析··········································································································· 95
第三节 国内CRO 市场细分前景··········································································································96
一 临床试验CRO 市场规模········································································································· 96
二 临床试验CRO 市场前景········································································································· 96
三 国内CRO 市场潜在机会········································································································· 98
第四节 国内CRO 市场竞争格局··········································································································98
第6 页 共141 页
一 国内CRO 企业性质类型········································································································· 99
二 国内CRO 企业业务类型········································································································· 99
第五节 国内CRO 产业联盟一览········································································································100
一 中国生物技术外包联盟（ABO） ························································································· 100
二 中关村CRO 联盟·················································································································· 101
三 浦东新区生物医药研发外包服务联盟·················································································· 102
四 医药研发外包联盟 CROSA·································································································· 103
第六节 2008-2009 年行业最新动态····································································································105
一 诺凡麦完成第二轮融资········································································································· 105
二 2008 年1 月桑迪亚医药完成第二轮风投融资····································································· 105
三 NovaSecta 公司首入我国医药研发外包公司联盟································································ 106
四 CRO 泰格医药科技获启明创投第一轮注资········································································· 106
五 张江集团联手桑迪亚医药 新药研发外包捆绑风投···························································· 107
六 泰格医药与启明创投联合注资生物统计CRO 美斯达························································ 108
第六章 2008-2009 年医药研发外包区域市场···············································109
第一节 北京医药研发外包···················································································································111
一 医药研发服务市场规模及结构······························································································111
二 北京医药研发外包服务技术市场··························································································111
三 北京医药研发外包服务优势领域分析·················································································· 113
第二节 上海医药研发外包···················································································································113
一 2008 年上海医药研发外包市场规模····················································································· 113
二 上海张江药谷研发外包分析································································································· 114
第三节 南京医药研发外包···················································································································116
一 2008 年南京医药研发外包市场规模····················································································· 116
二 南京研发外包市场优势分析································································································· 116
第7 页 共141 页
第七章 2008-2009 年国内CRO 企业分析···················································117
第一节 药明康德···································································································································117
一 企业概况································································································································ 117
二 公司业务结构························································································································ 117
三 竞争力swot 分析··················································································································· 118
四 2008 年财务运行分析············································································································ 120
第二节 万全科技···································································································································121
一 企业概况································································································································ 121
二 业务结构分析························································································································ 122
三 万全CRO 优势······················································································································ 123
四 2008 年财务运行···················································································································· 128
第三节 其他企业扫描···························································································································129
一 上海睿智化学························································································································ 129
二 桑迪亚医药技术（上海） ····································································································· 130
三 北京美迪生···························································································································· 131
四 北京凯维斯医药····················································································································· 133
五 北京依格斯医药技术发展有限公司······················································································ 134
六 泰格医药科技有限公司········································································································· 135
八 广州博济国家新药临床研究中心························································································· 138
九 康龙化成（北京）新药技术有限公司·················································································· 140
十 保诺科技（北京）有限公司································································································· 141
重要声明··················································································································································141

fhw99

好资料 谢谢!

maxsese

不客气～～